Marked and rapid effects of pharmacological HIF-2α antagonism on hypoxic ventilatory control

Hypoxia-inducible factor (HIF) is strikingly upregulated in many types of cancer, and there is great interest in applying inhibitors of HIF as anticancer therapeutics. The most advanced of these are small molecules that target the HIF-2 isoform through binding the PAS-B domain of HIF-2α. These molec...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Xiaotong, Prange-Barczynska, Maria, Fielding, James W., Zhang, Minghao, Burrell, Alana L., Lima, Joanna D.C.C., Eckardt, Luise, Argles, Isobel L.A., Pugh, Christopher W., Buckler, Keith J., Robbins, Peter A., Hodson, Emma J., Bruick, Richard K., Collinson, Lucy M., Rastinejad, Fraydoon, Bishop, Tammie, Ratcliffe, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190921/
https://www.ncbi.nlm.nih.gov/pubmed/31999648
http://dx.doi.org/10.1172/JCI133194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190921/
https://www.ncbi.nlm.nih.gov/pubmed/31999648
http://dx.doi.org/10.1172/JCI133194

Ejemplares similares